Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for lymphoma patients

NCT ID NCT01286272

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two different drug combinations for people with a type of blood cancer called follicular lymphoma that had not been treated before. One group received ofatumumab and bendamustine, while the other got those two drugs plus bortezomib. The goal was to see which combination led to more complete remissions, where all signs of cancer disappear. The trial involved 135 adults with stage III or IV disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

135 people

The number who actually took part.

Started

Apr 2011

Finished

Sep 2025

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed follicular non-Hodgkin lymphoma, World Health Organization (WHO) classification grade 1, 2, or 3a (\> 15 centroblasts per high-power field with centrocytes present) * Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies * Fine-needle aspirates are not acceptable * Failure to submit pathology within 60 days of patient registration will be considered a major protocol violation * Patients must have at least one of the following indicators of poor risk disease: * \>= 3 risk factors by the Follicular Lymphoma International Prognostic Index, or 2 risk factors by the Follicular Lymphoma International Prognostic Index and at least one bulky mass or lymph node \> 6 cm in size * Follicular Lymphoma International Prognostic Index (FLIPI score): * Age \> 60 years * Involvement of \> 4 nodal sites * Stage III-IV disease * Hemoglobin \< 12.0 g/dL * Lactate dehydrogenase (LDH) \> upper limit of normal (ULN) * 0-1 of the above risk factors: low risk * 2 risk factors: intermediate risk * \>= 3 risk factors: poor risk * No prior cytotoxic chemotherapy, radiotherapy, immunotherapy, or radioimmunotherapy * No corticosteroids are permitted, except for maintenance therapy for a non-malignant disease or to prevent treatment-related ofatumumab reactions (maintenance therapy dose must not exceed 20 mg/day prednisone or equivalent) * Measurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable; any tumor mass \> 1 cm is acceptable; lesions that are considered non-measurable include the following: * Bone lesions * Leptomeningeal disease * Ascites * Pleural/pericardial effusion * Inflammatory breast disease * Lymphangitis cutis/pulmonis * Bone marrow involvement (involvement by non-Hodgkin lymphoma should be noted) * Patients must have no known central nervous system (CNS) involvement by lymphoma * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Patients must be non-pregnant and non-nursing; pregnant or nursing patients may not be enrolled; women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to registration; in addition, women and men of childbearing potential must commit to use an effective form of contraception throughout their participation in this study; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier method (diaphragm plus condom) * Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; CD4+ count \> 400/ul; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load \< 50 copies HIV RNA/mL; no history of acquired immunodeficiency syndrome (AIDS)-defining conditions; no zidovudine or stavudine are allowed owing to overlapping toxicity with chemotherapy * Patients must have no evidence of active hepatitis B or C infection (i.e., no positive serology for anti-hepatitis B core \[HBc\] or anti-hepatitis C virus \[HCV\] antibodies); hepatitis B virus (HBV) seropositive patients (hepatitis B surface antigen \[HBsAg\] +) are eligible if HBV deoxyribonucleic acid (DNA) is undetectable at baseline and they are closely monitored for evidence of active HBV infection by HBV DNA testing at each treatment cycle; after completing treatment, HBsAg + patients must be monitored by HBV DNA testing every 2 months for 6 months post-treatment, while continuing lamivudine * Granulocytes \>= 1,000/uL * Platelet count \>= 75,000/uL * Creatinine =\< 2.0 mg/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x upper limits of normal (ULN) * Bilirubin =\< 2 x ULN

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ann arbor stage III grade 1 follicular lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Altru Cancer Center

    Grand Forks, North Dakota, 58201, United States

  • Annie Penn Memorial Hospital

    Reidsville, North Carolina, 27320, United States

  • Benefis Sletten Cancer Institute

    Great Falls, Montana, 59405, United States

  • Billings Clinic Cancer Center

    Billings, Montana, 59101, United States

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois, 62526, United States

  • Castle Medical Center

    Kailua, Hawaii, 96734, United States

  • Central Care Cancer Center - Bolivar

    Bolivar, Missouri, 65613, United States

  • Cone Health Cancer Center

    Greensboro, North Carolina, 27403, United States

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan, 49503, United States

  • CoxHealth South Hospital

    Springfield, Missouri, 65807, United States

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    Lebanon, New Hampshire, 03756, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • ECU Health Oncology Kinston

    Kinston, North Carolina, 28501, United States

  • Eastern Maine Medical Center

    Bangor, Maine, 04401, United States

  • Fairview Ridges Hospital

    Burnsville, Minnesota, 55337, United States

  • Fairview Southdale Hospital

    Edina, Minnesota, 55435, United States

  • Fort Wayne Medical Oncology and Hematology Inc-Parkview

    Fort Wayne, Indiana, 46845, United States

  • Franciscan Health Indianapolis

    Indianapolis, Indiana, 46237, United States

  • Guthrie Medical Group PC-Robert Packer Hospital

    Sayre, Pennsylvania, 18840, United States

  • Harold Alfond Center for Cancer Care

    Augusta, Maine, 04330, United States

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii, 96813, United States

  • Hawaii Cancer Care Inc-Liliha

    Honolulu, Hawaii, 96817, United States

  • Hematology Oncology Associates of Central New York-East Syracuse

    East Syracuse, New York, 13057, United States

  • Henry Ford Health Saint John Hospital

    Detroit, Michigan, 48236, United States

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426, United States

  • Iredell Memorial Hospital

    Statesville, North Carolina, 28677, United States

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii, 96826, United States

  • Kettering Medical Center

    Kettering, Ohio, 45429, United States

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho, 83854, United States

  • Kuakini Medical Center

    Honolulu, Hawaii, 96817, United States

  • Long Island Jewish Medical Center

    New Hyde Park, New York, 11040, United States

  • MU Health - University Hospital/Ellis Fischel Cancer Center

    Columbia, Missouri, 65212, United States

  • Memorial Hospital of South Bend

    South Bend, Indiana, 46601, United States

  • Memorial Regional Cancer Center Day Road

    Mishawaka, Indiana, 46545, United States

  • Mercy Health - Saint Anne Hospital

    Toledo, Ohio, 43623, United States

  • Mercy Hospital

    Cedar Rapids, Iowa, 52403, United States

  • Mercy Hospital Oklahoma City

    Oklahoma City, Oklahoma, 73120, United States

  • Mercy Hospital Saint Louis

    St Louis, Missouri, 63141, United States

  • Mercy Hospital Springfield

    Springfield, Missouri, 65804, United States

  • Miami Valley Hospital North

    Dayton, Ohio, 45415, United States

  • Michiana Hematology Oncology PC-Mishawaka

    Mishawaka, Indiana, 46545, United States

  • Michiana Hematology Oncology PC-Westville

    Westville, Indiana, 46391, United States

  • Middlesex Hospital

    Middletown, Connecticut, 06457, United States

  • Minneapolis VA Medical Center

    Minneapolis, Minnesota, 55417, United States

  • Minnesota Oncology Hematology PA-Maplewood

    Maplewood, Minnesota, 55109, United States

  • Missouri Baptist Medical Center

    St Louis, Missouri, 63131, United States

  • Mount Sinai Medical Center

    Miami Beach, Florida, 33140, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Nevada Cancer Research Foundation NCORP

    Las Vegas, Nevada, 89120, United States

  • North Shore University Hospital

    Manhasset, New York, 11030, United States

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois, 60201, United States

  • Northwell Health NCORP

    Lake Success, New York, 11042, United States

  • Northwell Health/Center for Advanced Medicine

    Lake Success, New York, 11042, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Oncology Associates at Mercy Medical Center

    Cedar Rapids, Iowa, 52403, United States

  • Pali Momi Medical Center

    ‘Aiea, Hawaii, 96701, United States

  • Park Nicollet Clinic - Saint Louis Park

    Saint Louis Park, Minnesota, 55416, United States

  • Penobscot Bay Medical Center

    Rockport, Maine, 04856, United States

  • ProMedica Flower Hospital

    Sylvania, Ohio, 43560, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Providence Saint Vincent Medical Center

    Portland, Oregon, 97225, United States

  • Queen's Cancer Center - Pearlridge

    ‘Aiea, Hawaii, 96701, United States

  • Queen's Medical Center

    Honolulu, Hawaii, 96813, United States

  • Randolph Hospital

    Asheboro, North Carolina, 27203, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho, 83706, United States

  • Saint Charles Hospital

    Oregon, Ohio, 43616, United States

  • Saint Francis Cancer Center

    Greenville, South Carolina, 29607, United States

  • Saint Francis Hospital

    Greenville, South Carolina, 29601, United States

  • Saint Helena Hospital

    St. Helena, California, 94574, United States

  • Saint John's Hospital - Healtheast

    Maplewood, Minnesota, 55109, United States

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri, 64111, United States

  • Sinai Hospital of Baltimore

    Baltimore, Maryland, 21215, United States

  • Siouxland Regional Cancer Center

    Sioux City, Iowa, 51101, United States

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Spartanburg Medical Center

    Spartanburg, South Carolina, 29303, United States

  • Springfield Clinic

    Springfield, Illinois, 62702, United States

  • Springfield Memorial Hospital

    Springfield, Illinois, 62781, United States

  • State University of New York Upstate Medical University

    Syracuse, New York, 13210, United States

  • Straub Clinic and Hospital

    Honolulu, Hawaii, 96813, United States

  • Toledo Clinic Cancer Centers-Maumee

    Maumee, Ohio, 43537, United States

  • Toledo Clinic Cancer Centers-Toledo

    Toledo, Ohio, 43623, United States

  • Trinity Health Grand Rapids Hospital

    Grand Rapids, Michigan, 49503, United States

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor

    Ann Arbor, Michigan, 48106, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

  • University of Illinois

    Chicago, Illinois, 60612, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Wayne Memorial Hospital

    Goldsboro, North Carolina, 27534, United States

  • Weiss Memorial Hospital

    Chicago, Illinois, 60640, United States

  • West Virginia University Healthcare

    Morgantown, West Virginia, 26506, United States

  • Wilcox Memorial Hospital and Kauai Medical Clinic

    Lihue, Hawaii, 96766, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.